Balyasny Asset Management L.P. Has $42.83 Million Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Balyasny Asset Management L.P. increased its holdings in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 2,613.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 653,668 shares of the company's stock after buying an additional 629,581 shares during the period. Balyasny Asset Management L.P.'s holdings in AstraZeneca were worth $42,828,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently added to or reduced their stakes in the company. World Investment Advisors LLC raised its holdings in shares of AstraZeneca by 115.5% in the 3rd quarter. World Investment Advisors LLC now owns 8,267 shares of the company's stock valued at $644,000 after purchasing an additional 4,430 shares in the last quarter. Tidal Investments LLC increased its position in AstraZeneca by 5.8% during the third quarter. Tidal Investments LLC now owns 6,649 shares of the company's stock worth $518,000 after buying an additional 362 shares during the period. Versant Capital Management Inc boosted its holdings in shares of AstraZeneca by 2,618.5% in the fourth quarter. Versant Capital Management Inc now owns 734 shares of the company's stock valued at $48,000 after acquiring an additional 707 shares during the period. Nordea Investment Management AB purchased a new position in shares of AstraZeneca during the fourth quarter worth approximately $754,000. Finally, Legacy Wealth Management LLC MS raised its position in AstraZeneca by 27.3% in the 4th quarter. Legacy Wealth Management LLC MS now owns 3,948 shares of the company's stock valued at $259,000 after purchasing an additional 846 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company's stock.

AstraZeneca Stock Up 0.4 %

Shares of AstraZeneca stock traded up $0.27 during trading hours on Friday, hitting $67.57. 6,215,921 shares of the company's stock traded hands, compared to its average volume of 5,141,616. The company has a quick ratio of 0.74, a current ratio of 0.93 and a debt-to-equity ratio of 0.65. AstraZeneca PLC has a twelve month low of $61.24 and a twelve month high of $87.68. The stock has a 50 day simple moving average of $71.33 and a 200-day simple moving average of $69.70. The company has a market cap of $209.55 billion, a PE ratio of 29.90, a PEG ratio of 1.42 and a beta of 0.40.

AstraZeneca (NASDAQ:AZN - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, beating analysts' consensus estimates of $1.10 by $0.14. The company had revenue of $13.59 billion during the quarter, compared to the consensus estimate of $13.71 billion. AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. The company's quarterly revenue was up 7.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.06 EPS. Equities research analysts anticipate that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Morgan Stanley started coverage on shares of AstraZeneca in a research note on Wednesday, February 12th. They issued an "overweight" rating on the stock. BNP Paribas began coverage on AstraZeneca in a research report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price objective for the company. Finally, UBS Group upgraded shares of AstraZeneca from a "neutral" rating to a "buy" rating in a research note on Thursday, February 13th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $88.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.